Chargement en cours...
CTGF is a therapeutic target for metastatic melanoma
Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3965577/ https://ncbi.nlm.nih.gov/pubmed/23435419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2013.47 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|